Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 10, 2010, Pages 1876-1882

  Kasper, Bernd ^a   Dimitrakopoulou Strauss, Antonia ^b   Strauss, Ludwig G ^b   Hohenberger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Aggressive fibromatosis; Desmoid tumours; Fluorodeoxyglucose; Imatinib; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DESMOID TUMOR; DISEASE COURSE; EDEMA; FATIGUE; FEMALE; FIBROMATOSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; METABOLISM; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; BIOLOGICAL TRANSPORT; FEMALE; FIBROMATOSIS, AGGRESSIVE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; TREATMENT OUTCOME;

EID: 79952114035     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1498-x     Document Type: Article

References (38)

1. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000;1:262-6.
2. Micke O, Seegenschmiedt MH. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study. Int J Radiat Oncol Biol Phys 2005;61:882-91.
3. Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, et al. Hereditary colorectal tumor registry. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003;21:1698-707.
4. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996;83:1494-504.
5. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181-90.
6. Pignatti G, Barbanti-Bròdano G, Ferrari D, Gherlinzoni F, Bertoni F, Bacchini P, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000;375:207-13.
7. Knudsen AL, Bülow S. Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam Cancer 2001;1:111-9.
8. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY, ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii89-93.
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
10. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
11. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
12. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
13. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
14. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
15. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
16. Mace J, Sybill BJ, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-9.
17. Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58:1152-6.
18. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour). J Clin Oncol 2006;24:1195-203.
19. Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Guillemet C, Cupissol D, et al. Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group. ASCO Meeting abstrcts 2006, 24:9516.
20. Dufresne A, Penel N, Salas S, Le Cesne A, Perol D, Bui B, et al. Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/French Sarcoma Group phase II trial. ASCO Meeting abstracts 2009, 27:10518.
21. Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. ASCO Meeting abstrcts 2006, 24:9515.
22. Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002;20:3156-64.
23. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
24. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig G, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible? Eur J Nucl Med Mol Imaging 1999;26:599-605.
25. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998;39:250-4.
26. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-48.
27. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-73.
28. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopatho-logical grading system. Int J Cancer 1984;33:37-42.
29. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241:286-94.
30. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519-27.
31. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818-23.
32. Cheng EY, Froelich JW, Manivel JC, Weigel J, Skubitz KM. Correlation of FDG PET-CT with histologic response after neoadjuvant chemotherapy for soft tissue sarcomas. ASCO Meeting abstracts 2009, 27:10583.
33. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, et al. Early prediction of therapy outcome in patients with high risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107-12.
34. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433-8.
35. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
36. Ramos-Font C, Santiago Chinchilla A, Rebollo Aguirre AC, Rodríguez Fernández A, Medina Benítez A, Llamas Elvira JM. Desmoid tumor of the thoraco-abdominal wall characterized with 18F-fluorodeoxyglucose PET/CT scan. Correlation with magnetic resonance and bone scintigraphy. Review of the literature. Rev Esp Med Nucl 2009;28:70-3.
37. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010. doi:10.1007/s00259- 010-1435-z.
38. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010;51:551-8.